Abstract 4503
Background
NAVYA is a validated online cancer informatics solution that combines artificial intelligence (AI) and rapid review (2 mins/case) by multi-disciplinary tumor board experts at Academic Medical Centers (AMC) to deliver multidisciplinary expert treatment plan to patients within 24 hours. Initially developed for patients in India without ready access to expertise, over 28,000 patients across 68 countries have since reached out to NAVYA. Prior research (SABCS and ASCO 2014-2018) showed, 1) 97% concordance of NAVYA with an AMC in India and in the US 2) 97% of patients experienced significant anxiety relief due to 24 hours turnaround time. NAVYA scales access to expertise unlike the limitations of synchronized 1 patient: 1 doctor consults in telemedicine.
Methods
Three patient centered outcomes (travel distance, cost and time to receive expert treatment plan) were studied. All consecutive patients who reached out to NAVYA between 1/1/17-1/31/19 but ultimately opted for in-person visit to an AMC were contacted by prospective phone follow up. This was compared to a numerically balanced random sample of patients who only used NAVYA to obtain treatment plans.
Results
Prospective phone follow-ups with 902 in-person patients and 901 NAVYA patients were analyzed. The groups did not differ significantly in demographics or disease characteristics. In-person patients and NAVYA patients differed significantly with respect to 1) median travel distance (761 miles, IQR (152 -1083 miles) vs. 0 miles (p < 0.05)) 2) travel related costs of $1250 [95% CI +/- $54.5] vs $105 online processing fee 3) total time to receipt of treatment plan (4.66 days, IQR (0.4 - 20.3 days) vs. 1.04 day IQR (0.4-2.5) (p < 0.05)).
Conclusions
Cancer informatics solutions that combine AI with human clinical expertise to generate multidisciplinary treatment plans tailored to an individual patient, and vetted by experts at AMC, scale ready access to expertise around the world. For patients with limited access to AMC, such solutions eliminate travel burden, and significantly reduce cost and wait time. This has significant implications for creating access to specialty expertise, globally.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
5389 - Two-weekly accelerated BEP (aBEP) regimen as induction chemotherapy (CT) in intermediate and poor prognosis patients (pts) with nonseminomatous germ cell tumors (NSGCT): final results of phase II trial.
Presenter: Alexey Tryakin
Session: Poster Display session 3
Resources:
Abstract
2934 - Differential expression of circulating miR375 and miR371 to detect teratoma and viable germ cell malignancy
Presenter: Lucia Nappi
Session: Poster Display session 3
Resources:
Abstract
3585 - Prognosis of anaemia in disseminated testicular germ cell tumours. On behalf of the Spanish Germ Cell Cancer Group (SGCCG)
Presenter: Esmeralda Garcia Torralba
Session: Poster Display session 3
Resources:
Abstract
2254 - The Effects Of Primary Testicular Tumor Localization On Prognosis In Patients With Nonseminomatous Testis Cancer
Presenter: Birol Yildiz
Session: Poster Display session 3
Resources:
Abstract
4505 - Initial Results of a Phase II study of Nivolumab and Ipilimumab in Metastatic Adrenal Tumors.
Presenter: Matthew Campbell
Session: Poster Display session 3
Resources:
Abstract
3369 - NEMIO: a randomized phase II trial evaluating efficacy and safety of dose dense MVAC (ddMVAC) + durvalumab +/- tremelimumab as neoadjuvant treatment in patients with bladder muscle-invasive urothelial carcinoma
Presenter: Constance Thibault
Session: Poster Display session 3
Resources:
Abstract
2075 - KEYNOTE-866: Phase 3 Study of Perioperative Pembrolizumab (pembro) or Placebo (pbo) in Combination With Neoadjuvant Chemotherapy in Cisplatin (cis)-Eligible Patients (pts) With Muscle-Invasive Bladder Cancer (MIBC)
Presenter: Arlene Siefker-Radtke
Session: Poster Display session 3
Resources:
Abstract
4824 - KEYNOTE-905: A Phase 3 Study of Cystectomy Plus Perioperative Pembrolizumab Versus Cystectomy Alone in Cisplatin (cis)-Ineligible Patients (pts) With Muscle-Invasive Bladder Cancer (MIBC)
Presenter: Matthew Galsky
Session: Poster Display session 3
Resources:
Abstract
2253 - Phase 3 LEAP-011 trial: First-Line Pembrolizumab With Lenvatinib in Patients With Advanced Urothelial Carcinoma Ineligible to Receive Platinum-Based Chemotherapy
Presenter: Yohann Loriot
Session: Poster Display session 3
Resources:
Abstract
4310 - PULSE : A Single Arm Trial Assessing The Activity and Safety of Avelumab Immunotherapy Maintenance among Patients With Locally Advanced or Metastatic Squamous Cell Penile Carcinoma (mSCPC).
Presenter: Noemie Gassian
Session: Poster Display session 3
Resources:
Abstract